Mechanism of Action

TPL101 inhibits a critical nuclear import protein involved in the replication cycle of multiple viruses. This mechanism of action should allow TPL101 to be consistently effective against a range of respiratory viruses, including coronaviruses such as COVID-19 and Avian influenza, as well as Flaviviridae family viruses like Dengue, Zika, and Yellow Fever. Additionally, TPL101's mechanism is likely strain-agnostic, meaning it should combat various strains of these viruses.

In our studies, TPL101 has demonstrated significant anti-inflammatory properties, reducing the expression of multiple pro-inflammatory markers, including IL-1β, IL-6, TNF-α, IP-10, IFN-λ1, and IFN-γ, among others. This anti-inflammatory effect further enhances its potential as a versatile and potent antiviral therapy.